Related Experiment Video
Updated: Jan 12, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.5K
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice
Meena B Bansal1, Heather Patton2,3, Timothy R Morgan4,5
1Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Hepatology (Baltimore, Md.)
|November 7, 2025
Summary
Semaglutide shows promise for treating metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced fibrosis, improving liver histology and fibrosis. Careful patient selection and monitoring are crucial for safety and efficacy.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD), previously NAFLD, is a growing health concern.
- Current management relies heavily on lifestyle modifications, with limited pharmacologic options for advanced stages.
- Semaglutide has emerged as a potential therapeutic agent for MASLD.
Purpose of the Study:
- To provide updated practice guidance on semaglutide for MASLD management.
- To outline patient selection criteria for semaglutide treatment.
- To detail monitoring strategies for treatment safety and efficacy.
Main Methods:
- Review of the phase 3 ESSENCE trial data for semaglutide in MASH.
- Utilizing noninvasive tests (NITs) like VCTE, MRE, and ELF for patient selection.
- Monitoring for treatment response and adverse events.
Main Results:
- Semaglutide (2.4 mg/week) demonstrated significant improvements in MASH resolution and fibrosis reduction in the ESSENCE trial.
- Noninvasive tests are recommended for identifying candidates with F2-F3 fibrosis.
- Common adverse events were gastrointestinal; serious risks require careful monitoring.
Conclusions:
- Semaglutide offers a new treatment avenue for MASH with moderate to advanced fibrosis.
- Noninvasive testing facilitates practical patient selection, reducing the need for liver biopsy.
- Ongoing monitoring is essential to manage potential risks and assess treatment response.
More Related Videos
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
303
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
303
01:24Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
01:26Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
01:26Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
01:20Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
01:30Acute Pancreatitis II: Clinical Manifestations and Management
713
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
713